CD19 and plasma cell myeloma: Impressively, T cells isolated from multiple myeloma patients engineered to be CD19 specific and expanded in 1B2H SFM provided durable control of tumor in all mice treated and had equivalent therapeutic potency as similarly engineered and expanded T cells isolated from a healthy donor.